收费全文 | 234317篇 |
免费 | 18570篇 |
国内免费 | 7742篇 |
耳鼻咽喉 | 1824篇 |
儿科学 | 4207篇 |
妇产科学 | 3273篇 |
基础医学 | 35974篇 |
口腔科学 | 4424篇 |
临床医学 | 16714篇 |
内科学 | 43161篇 |
皮肤病学 | 3305篇 |
神经病学 | 17255篇 |
特种医学 | 5904篇 |
外国民族医学 | 54篇 |
外科学 | 18551篇 |
综合类 | 28346篇 |
现状与发展 | 22篇 |
一般理论 | 6篇 |
预防医学 | 12399篇 |
眼科学 | 2342篇 |
药学 | 34549篇 |
68篇 | |
中国医学 | 8838篇 |
肿瘤学 | 19413篇 |
2023年 | 4317篇 |
2022年 | 9456篇 |
2021年 | 11612篇 |
2020年 | 8811篇 |
2019年 | 8600篇 |
2018年 | 8249篇 |
2017年 | 7585篇 |
2016年 | 7321篇 |
2015年 | 8440篇 |
2014年 | 13162篇 |
2013年 | 14538篇 |
2012年 | 12475篇 |
2011年 | 14337篇 |
2010年 | 11792篇 |
2009年 | 12132篇 |
2008年 | 11686篇 |
2007年 | 10652篇 |
2006年 | 9560篇 |
2005年 | 8357篇 |
2004年 | 7007篇 |
2003年 | 6354篇 |
2002年 | 4996篇 |
2001年 | 4127篇 |
2000年 | 3535篇 |
1999年 | 3201篇 |
1998年 | 2906篇 |
1997年 | 2703篇 |
1996年 | 2415篇 |
1995年 | 2106篇 |
1994年 | 1912篇 |
1993年 | 1625篇 |
1992年 | 1371篇 |
1991年 | 1298篇 |
1990年 | 1065篇 |
1989年 | 910篇 |
1988年 | 865篇 |
1987年 | 725篇 |
1986年 | 650篇 |
1985年 | 1902篇 |
1984年 | 2634篇 |
1983年 | 1688篇 |
1982年 | 1828篇 |
1981年 | 1671篇 |
1980年 | 1390篇 |
1979年 | 1207篇 |
1978年 | 1013篇 |
1977年 | 859篇 |
1976年 | 959篇 |
1975年 | 666篇 |
1973年 | 626篇 |
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献Methods: [11C]WAY100635, [18F]altanserin and positron emission tomography were used to compare 5-HT1A and 5-HT2A binding in MDD patients divided into eight past suicide attempters (>4yrs prior to scanning) and eight lifetime non-attempters, and both groups were compared to eight healthy volunteers.
Results: The two receptor types differed in binding pattern across brain regions from each other, but there were no differences in binding between healthy volunteers and the two depressed groups or between depressed suicide attempters and non-attempters. No effects of depression severity or lifetime aggression were observed for either receptor.
Conclusion: Limitations of this study include small sample size and absence of high lethality suicide attempts in the depressed attempter group. No trait-like binding correlations with past suicide attempt or current depression were observed. Given the heterogeneity of nonfatal suicidal behavior, a larger sample study emphasizing higher lethality suicide attempts may find the serotonin biological phenotype seen in suicide decedents. 相似文献